Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal 
Dollar Steadies Ahead of ECB and BoE Decisions as Markets Turn Risk-Off 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Trump’s Inflation Claims Clash With Voters’ Cost-of-Living Reality 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Instagram Outage Disrupts Thousands of U.S. Users 
South Korea’s Weak Won Struggles as Retail Investors Pour Money Into U.S. Stocks 
Silver Prices Plunge in Asian Trade as Dollar Strength Triggers Fresh Precious Metals Sell-Off 
Bank of Japan Signals Readiness for Near-Term Rate Hike as Inflation Nears Target 
U.S. Stock Futures Slide as Tech Rout Deepens on Amazon Capex Shock 
Samsung C&T attributed its first-quarter net profit surge of 55.8 percent to equity gains from its affiliate Samsung Biologics and profitable overseas projects.
The company, a construction affiliate of the Samsung Group, said in a regulatory filing that it had a net profit of 346.5 billion won for January to March, up from 222.4 billion won in the same period a year before.
Samsung C&T owns a 43.3 percent share in Samsung Biologics, a biopharmaceutical unit of Samsung Group.
The company claimed a first-quarter increase of 39.8 percent in its operating profit to 147 billion from 105 billion won in the same period last year.
However, Samsung C&T's revenue of 6.96 trillion won is a 5.4 percent dip from 7.35 trillion won last year. It attributed the drop to decreasing domestic consumption, and trading volume brought about by the COVID-19 situation, and for the completion of construction projects undertaken by the company.
Shares in Samsung C&T is up 3.3 percent to 97,000 won, outperforming KOSPI's gain of 0.89 percent gain.
"Increased equity gains from Samsung Biologics and profitable overseas projects boosted the first-quarter net profit," an official of Samsung C&T said.
